Rein Therapeutics Inc. has announced new scientific findings regarding its lead drug candidate, LTI-03, for idiopathic pulmonary fibrosis (IPF). A recently posted preprint on medRxiv describes results from a randomized, dose-escalation clinical study evaluating inhaled LTI-03 in IPF patients. The study assessed safety, pharmacokinetics, and biological activity. According to the report, LTI-03 was generally well tolerated and was associated with reductions in multiple fibrosis-associated biomarkers, as well as preservation of alveolar epithelial type II progenitor cells, which are important for lung repair. These findings build on previous results and provide support for the ongoing global Phase 2 RENEW trial of LTI-03. The results have already been made available in the preprint publication.